Prot #ALKS 4230-007/GOG-3063: A Phase 3, Multicenter, Open Label, Randomized Trial of Nemvaleukin Alfa in Combination with Pembrolizumab Versus Investigator's Choice Chemotherapy in Patients with Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or P

Project: Research project

Project Details

StatusActive
Effective start/end date2/28/23 → 2/28/26

Funding

  • Gynecologic Oncology Group (Prot #ALKS 4230-007/GOG-3063)
  • Alkermes, Inc. (Prot #ALKS 4230-007/GOG-3063)